Cargando…

Predicting microvascular invasion in hepatocellular carcinoma: A dual‐institution study on gadoxetate disodium‐enhanced MRI

BACKGROUND & AIMS: Microvascular invasion (MVI) is an important risk factor in hepatocellular carcinoma (HCC), but its diagnosis mandates postoperative histopathologic analysis. We aimed to develop and externally validate a predictive scoring system for MVI. METHODS: From July 2015 to November 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Hanyu, Wei, Jingwei, Fu, Fangfang, Wei, Hong, Qin, Yun, Duan, Ting, Chen, Weixia, Xie, Kunlin, Lee, Jeong Min, Bashir, Mustafa R., Wang, Meiyun, Song, Bin, Tian, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Liver Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314889/ https://www.ncbi.nlm.nih.gov/pubmed/35243749 http://dx.doi.org/10.1111/liv.15231

Ejemplares similares

Analysis of the Performance of Gadoxetic Acid Disodium MRI in Predicting Microvascular Invasion of Hepatocellular Carcinoma
por: Chen, Jiao, et al.
Publicado: (2022)

Predicting histologic differentiation of solitary hepatocellular carcinoma up to 5 cm on gadoxetate disodium-enhanced MRI
por: Yang, Ting, et al.
Publicado: (2023)

Benign nodules mimicking hepatocellular carcinoma on gadoxetic acid-enhanced liver MRI
por: Song, Kyoung Doo, et al.
Publicado: (2015)

Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma
por: Wang, Dong, et al.
Publicado: (2020)

Hepatocellular carcinoma composed of two different histologic types: imaging features on gadoxetic acid-enhanced liver MRI
por: Kim, Seung Hyun, et al.
Publicado: (2013)

Preoperative prediction of glypican-3 positive expression in solitary hepatocellular carcinoma on gadoxetate-disodium enhanced magnetic resonance imaging
por: Chen, Yidi, et al.
Publicado: (2022)

Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers
por: Lochrin, Sarah E., et al.
Publicado: (2021)

Gadoxetate Disodium enhanced spectral dual-energy CT for evaluation of cholangiocarcinoma: Preliminary data
por: Thomas, John V., et al.
Publicado: (2016)

Multi-scale and multi-parametric radiomics of gadoxetate disodium–enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm
por: Chong, Huan-Huan, et al.
Publicado: (2021)

Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver
por: Huh, Jimi, et al.
Publicado: (2015)

Safety profile of gadoxetate disodium in elderly patients (≥65 years)
por: Endrikat, Jan, et al.
Publicado: (2017)

Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC
por: Cannella, Roberto, et al.
Publicado: (2022)

Quantification of liver function using gadoxetic acid-enhanced MRI
por: Poetter-Lang, Sarah, et al.
Publicado: (2020)

Influence of age on gadoxetic acid disodium-induced transient respiratory motion artifacts in pediatric liver MRI
por: Hojreh, Azadeh, et al.
Publicado: (2022)

Does gadoxetate disodium affect MRE measurements in the delayed hepatobiliary phase?
por: Plaikner, M., et al.
Publicado: (2018)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
por: Park, Joong-Won, et al.
Publicado: (2015)

A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection
por: Klompenhouwer, Anne J., et al.
Publicado: (2020)

Hepatocellular adenoma in men: A nationwide assessment of pathology and correlation with clinical course
por: van Rosmalen, Belle V., et al.
Publicado: (2021)

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
por: Labeur, Tim A., et al.
Publicado: (2019)

Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
por: Prawira, Aldo, et al.
Publicado: (2020)

Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis
por: Costentin, Charlotte E., et al.
Publicado: (2022)

Evaluation of transient respiratory motion artifact at gadoxetate disodium-enhanced MRI—Influence of different contrast agent application protocols
por: Ringe, Kristina I., et al.
Publicado: (2018)

Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma
por: Gao, Xu-dong, et al.
Publicado: (2014)

Interaction of FGF9 with FGFR3‐IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma
por: Paur, Jakob, et al.
Publicado: (2020)

Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging for the Detection of Hepatocellular Carcinoma: A Meta-Analysis
por: Liu, Xijiao, et al.
Publicado: (2013)

Improved visualisation of hepatic metastases in gadoxetate disodium-enhanced MRI: Potential of contrast-optimised (phase-sensitive) inversion recovery imaging
por: Fahlenkamp, Ute Lina, et al.
Publicado: (2019)

Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy
por: Chong, Huanhuan, et al.
Publicado: (2021)

Safety of gadoxetate disodium: results from six clinical phase IV studies in 8194 patients
por: Endrikat, Jan, et al.
Publicado: (2015)

Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study
por: Chiang, Nai‐Jung, et al.
Publicado: (2020)

Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence
por: Giordano, Silvia, et al.
Publicado: (2020)

Nationwide treatment and outcomes of perihilar cholangiocarcinoma
por: van Keulen, Anne‐Marleen, et al.
Publicado: (2021)

Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory
por: Li, Chenxi, et al.
Publicado: (2022)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Outcome of liver cancer patients with SARS‐CoV‐2 infection: An International, Multicentre, Cohort Study
por: Muñoz‐Martínez, Sergio, et al.
Publicado: (2022)

DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01
por: Jarman, Edward J., et al.
Publicado: (2022)

Respiratory anomalies associated with gadoxetate disodium and gadoterate meglumine: compressed sensing MRI revealing physiologic phenomena during the entire injection cycle
por: Glessgen, Carl Guillaume, et al.
Publicado: (2021)

Relative Enhancement in Gadoxetate Disodium-Enhanced Liver MRI as an Imaging Biomarker in the Diagnosis of Non-Alcoholic Fatty Liver Disease in Pediatric Obesity
por: Hojreh, Azadeh, et al.
Publicado: (2023)

Shrunken Hepatic Hemangioma Following Delineated Peritumoral Hyperintensity on Gadoxetic Acid Disodium-enhanced MR Imaging
por: Haradome, Hiroki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_reghkdr2ig0cse45fkg8bfq22i